Monoclonal antibodies are useful tools to study the function of growth factor receptors for which there is no known ligand. These may act either as agonists or as antagonists and thus give an insight into the physiological function of the receptor. Monoclonal antibodies have been raised in the past against the extracellular domain of both the epidermal growth factor receptor (EGFR) and c-erbB2 receptors which have been used to gain a greater understanding of the function of these proteins (Fernandez-Pol, 1985; Harwerth et al., 1993) . In addition, such reagents have potential value as vectors for novel therapeutic agents (Meyer et al., 1993; Trail et al., 1993) .
A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines T. Rajkumar Monoclonal antibodies are useful tools to study the function of growth factor receptors for which there is no known ligand. These may act either as agonists or as antagonists and thus give an insight into the physiological function of the receptor. Monoclonal antibodies have been raised in the past against the extracellular domain of both the epidermal growth factor receptor (EGFR) and c-erbB2 receptors which have been used to gain a greater understanding of the function of these proteins (Fernandez-Pol, 1985; Harwerth et al., 1993) . In addition, such reagents have potential value as vectors for novel therapeutic agents (Meyer et al., 1993; Trail et al., 1993) .
c-erbB3 belongs to the type I growth factor receptor family, whose other members include the EGFR, c-erbB2 and c-erbB4 proteins. Ligands have been identified for the EGFR (EGF, transforming growth factor alpha, amphiregulin, heparin-binding EGF and betaceluin) ) and c-erbB4 [heregulin/neu differentiation factor (NGF)] (Plowman et al., 1993a) . Very recently it has been shown that NDF/heregulin also binds to and stimulates the kinase activity of c-erbB3 (Kita et al., 1994) .
The EGFR and c-erbB2 receptors when expressed at high levels in NIH3T3 cells have transforming propertes, suggesting that they may act as dominant oncogenes. Among the four proteins, EGFR and c-erbB2 overxpression has been extensively studied in a variety of tumours at the DNA, mRNA and protein levels and where evaluated tends to be associated with poor prognosis (Gullick, 1991; Lofts & Gullick, 1991) . Much less, however, is known about c-erbB3 and c-erbB4.
The c-erbB3 receptor is epr d in normal human tissues, with high levs present in mature, differentiated cells of the gastrointestinal tract and in the neurons of the central nervous system. It has been found to be overexpressed in breast (Lemoine et al., 1992a) , gastrointestinal (Poller et al., 1992; Rajikumar et al., 1993; Sanidas et al., 1993) and pancreatic cancers (Lemoine et al., 1992b) (Rajkumar et al., 1994) no clones secreting specific antibodies were obtained from several fusions. The c-erbB3 protein was therefore parfially purified from detergent lsates of HER3 cells using wheat germ lctin Sepharose chromatography. This technique has been used previously to purify the human EGF receptor (Woltjer et al., 1992 ) and the c-erbB2 protein (N.L. Tuzi & WJ. Gullick, unpublished results) .
HER3 cells (human kidney fibroblasts transfected with the HER3 cDNA) (a kind gift from Dr G. Plowman) grown to confluence in a 175 cm2 flask were washed twice with phosphate-buffered saline (PBS) containing 2 mM ethylene glycol bis-tetracetic acid (EGTA) and then 5 ml of ice-cold lysis buffer (50 mM Tris-HCL pH 7.4, containing 1% Triton X-100, 5 mM EGTA, 150mM sodium chloride, 25 mM ben7amidine, 2 mM phenylmethylsulphonyl fluoride and I0jigml-' leupeptin) with I mgml-I bovine serum albumin (BSA) (Sigma, Poole, UK) was added. The lysate was spun at 3,000 r.p.m. for 10 min at 4-C and the superatant removed and placed on ice.
A 2 ml aliquot of wheat germ lectin Sepharose MB (Sigma) was washed twice with lysis buffer (10 ml per wash). The lysate was then added and tumbled for 1 h at 4C, and spun at 2,000 r.p.m. for 2 min. The supernatant was colled and placed on ice. The column was washed thrice with wash buffer 1 (0.5 M sodium chloride and 0.1% Triton X-100) and once with wash buffer 2 (50 mM HEPES, pH 7.4, 150mM sodium chloride and 0.1% Triton X-100). A 900 #il volume of elution buffer [50 mM HEPES, pH 7.4, 250 mM Nacetylucosamine (Sigma) and 0.1% Triton X-1001 was added and tumbled at 4-C for 15 min. The tube was spun as before and the eluate removed and stored and the process of elution repeated once more. The eluate samples were pooled together and concentrated using a Centricon 30 concentrator (Amicon, Beverly, USA) and then the protein concentration was estimated using the Bradford (1976) technique.
Immunisation with partially purified c-erbB3 protein Balb/c mice were injected subcutaneously with 30-50 Mg of wheat germ purified c-erbB3 protein at 2 weekly intervals, firstly with complete Freund's adjuvant and on the second and third occasions with incomplete Freund's adjuvant. The fourth dose was given a week after the third dose subcutaneously, and this was followed 6 weeks later by the fifth dose given without adjuvant, intraperitoneally. The mouse used for the fusion was boosted 5 weeks after the fifth dose, Br. J. Cawer (1994), 70, 459-465 C Maanilbn IN Ltd., 1994 with 100 gLg of the protein given intraperitoneally, and then killed 4 days later. grown overnight. The cells were washed in PBS and then 50 ng ml' NDF 2a (a generous gift from Dr Naili Liu, Amgen) or 25pgml-' SGPI in DMEM was added to the cells and incubated for 5 or 30mm respectively at 37C. As a negative control, medium alone was added to cells and incubated. The cells were washed twice in 1 ml of PBS-2.5 mM EGTA, 10 mM sodium fluoride, 10 mM sodium pyrophosphate and 1 mm sodium orthovanadate. The cells were lysed in lysis buffer containg 10 mm sodium fluoride, 10 mm sodium pyrophosphate, 1 mM sodium orthovanadate and 1 mg ml-' BSA. The lysates were spun, the supermatant removed and added to 10 id of agarose-antiphosphotyrosine antibody (Sigma) which had been washed once with PBS-EGTA containing 10 mM sodium fluoride, 10 mM sodium pyrophosphate and 1 mM sodium orthovanadate. The lysate and agarose-antibody complex were tumbled at 4-C for 2 h and then washed once with high-salt wash buffer (PBS containing an additional 350 mM sodium chloride and 0.2% Triton X-100) and twice with low-salt wash buffer (PBS conta g 0.2% Triton X-100), both containing 10 mM sodium fluoride, 1O mM sodium pyrophosphate and 1 mM sodium orthovanadate. After the final wash the supenatant was removed as completely as possible and 20 id of 5 x sample buffer was added and heated at IOOC for 5 min. The tubes were spun and the supermatant recovered and loaded onto a 7% SDS-PAGE gel and then Western blotted with 49.3 polyclonal antibody and detet using the ECL system (Amersham).
Effect on anchorage-independent growth BT483, T47D and 293 cells were grown to 75% confluence and then trypsinised and counted. The cells were resuspended in DMEM-F12 medium at 1.2 x 10" cells ml-'. SGP1 and an isotype-matched negative control antibody, both of which had been filter sterilised, were diluted in serum-free medium to lOOagml1'. Doubling dilutions of the antibodies were prepared and 700#l of each concentration of antibody was added to 300 #d of each cell suspension, along with 200 g1 of FCS. The antibody-cell suspension was incubated for 90 min at 37C.
A 0.5 ml aliquot of 0.5% Noble apr was added as a base layer to each well in a 24-well plate and allowed to set. A 1:3 dilution of 3% apr was mde in DMEM-F12 medium and 300 jid of the agar-meium mixture was added to each tube of cell suspension and mixed well. A 0.6 ml volme of this was then layered over the base layer and allowed to set. Duplicate samples were done for each dilution of antibody and cell hne. The plates were then plac in the incubator at 3rC. On day 8, 0.5 ml of the corresponding antibody was added diluted in DMEM-F12 medium On day 16, colonies more than 5 gn in size were counted. The P-value was calculated by chi-square test comparing the effect of SGPI antibody and the control antibody versus no additions for each of the cel lines.
The antibody recognised a protein of 160 kDa molcular weight in the HER3 cell lines but not in the other cell lines. The c-erbB3 protein in HER3 cells is expressed as a 160 kDa molcular weight protein Plowman et al., 1993b) human breast tumour cell lines (Kraus et al., 1993; Rajkumar et al., 1994) presumably as a result of differences in carbohydrate processng.
The SGP1 monoclonal antibody did not recognise c-erbB3
in Western blots of cell lysates prepared from the HER3 cells or in formalin-fixed, paraffin-embedded tissue sections previously known to be positive for c-erbB3 protein (data not shown). A protein of the correct size was, however, detected by other antipeptide antibodies raised against three cytoplasmic domain synthetic peptides , Two types of experiment were done to confirm that the SGPI antibody was directed to the extracellular domain of the receptor and could bind to live cells. Intact and detergent-permeabilised HER3 cells were treated with SGPI or 49.3 antibodies and their reaction detected using appropriate fluorescence-labelled second antibodies and UV microscopy. The polyclonal 49.3 antibody against a cytopLasmic epitope gave a positive fluorescence reaction with the HER3 cels only when they were permeabiised (Figure 3b ) and not when they were non-permeabilised (Figure 3a) , but the monoclonal SGPI antibody gave a positive reaction in nonpermeabiised (Figure 3c ) and permeabilised HER3 cells (Figure 3d) , suggesting that it reacts with the external domain of the c-erbB3 protein. The negative control antibody did not give any reaction under either conditions (Figure 3e and f) .
We next performed FACS analysis of a series of live cells that express or lack expression of the c-erbB3 protein. The FACS scan with live non-permeabilised 293 cells using the monoclonal SGPI was essentially negative. The HER3 and BT483 cells were positive with SGPI antibody but negative with the control antibody. However, the BT483 cells appear to have almost 100-fold kss c-erbB3 protein (Figure 4) sing the c-erbB3 protein but did not affect the cloning efficiency of 293 cells which lack the protein.
In the light of the effect on anchorageindependent growth,
we then attempted to demonstrate stimulation of the tyrosine FL1 log kinase activity of the c-erbB3 protein in HER3 and BT483 cells by the monoclonal antibody SGP1. In the unstimulated state the HER3 cells (Figure 6 , lane 5) showed a 160 kDa protein which increased in signal intensity 2-to 3-fold in the presence of NDF (Figure 6 , lane 1), indicating that NDF does indeed stimulate c-erbB3 kinase activity. In the presence of SGP1 antibody there is no obvious increase in the intensity of the signal in the HER3 cells ( Figure 6, lane 3) . No bands were vialised with the BT483 cells in the unstimulated state (Figure 6, lane 6) or in the presence of NDF or SGPI (Figure 6, lanes 2 and 4) .
Dio
We report here the production and characterisation of the monoclonal antibody SGP1 raised against the c-erbB3 protein using wheat germ purified cell lysate from HER3 cells that were enginred to overexpress the protein. This monoclonal antibody has been found to recognise the extracellular domain of the receptor as evidenced by its positive imunofluorescence reaction in non-permeabilised and permeabilised cells and its positive reaction in FACS with whole live cells. Treatment of the cells with tunicamycin, which inhibits the addition of N-linked sugars to the EGF receptor (Waterfield et al., 1982) and the c-erbB2 protein (Harwerth et al., 1992) , showed that the antibody recognises a protein epitope of the c-erbB3 extracellular domain.
The effect on the anchorage-independent growth of BT483 effect on anchorage-independent growth of breast tumour cell lines could be due to an initial effect on cell viability or to an effect on growth. The stimulation of anchorage-independent growth does not occur at concentrations above 25 1g ml-' SGPI antibody. This could be because high concentrations of antibody may lead to monovalent binding and not bivalent binding, which is required for cross-linking two receptor molecules so that they can dimerise and cross-phosphorylate each other. This effect has previously been demonstrated with platelet-derived growth factor (PDGF) receptor using either high levels of ligand (Heldin et al., 1989) or antibodies to the extracellular domain (Ronnstrand et al., 1988) . This is therefore supportive of c-erbB3 protein being activated by SGPI antibody by a dimerisation mechanism. We were unable to show a significant effect of the SGP1 antibody on the kinase activity of the c-erbB3 receptor, although NDF clearly stimulates the kinae activity of cerbB3 protein in the HER3 cells. The effect has not been seen in the breast tumour cell line BT483, presumably because of the almost 100-fold lower levels of the receptors expressed as demonstrated by FACS analysis.
Similar monoclonal antibodies have been raised against EGFR and c-erbB2 receptors and have been found to be either agonists or antagonists (Fernandez-Pol, 1985; Harwerth et al., 1992; Modjtahedi et al., 1993a, b) . These antibodies have been subsequently evaluated for therapeutic effects either on their own or following conjugation to toxins, radionuclides or drugs. The c-erbB3 protein has a distint expression in normal tissues of the gstrointestinal tract, bladder and skin, being present at high levels in the terminally differentiated cells of the mucosa and epidermis but absent or present only at very low levels in the proliferating basal cells. The lack of expression in proliferating cells or normal tissues and the overexpression in a range of solid human tumour types (Lemoine et al., 1992a, b; Poller et al., 1992; Rajkumar et al., 1993; Sanidas et al., 1993) makes it a suitable target for antibody-directed enzyme prodrug therapy (ADEPT). Studies using monoclonal antibodies to EGFR and c-erbB2 have shown a synergistic effect of combining the monoclonal antibody with chemotherapeutic agents such as doxorubicin and cisplatinum (Hancock et al., 1991; Baselga et al., 1993; Fan et al., 1993) . We therefore plan to evaluate the effect of the monoclonal antibody SGP1 on tumour xenografts, on its own, by conjugation to a prodrug system and by concurrent administration of chemotherapeutic agents.
